vimarsana.com

Page 3 - கட்டாயமாகும் மாற்றத்தக்கது ப்ரிஃபர்ட் ஸ்டாக் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Boston Scientific Announces Results For First Quarter 2021

Boston Scientific Announces Results For First Quarter 2021 News provided by Share this article Share this article MARLBOROUGH, Mass., April 28, 2021 /PRNewswire/  Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.752 billion during the first quarter of 2021. This represents growth of 8.2 percent on a reported basis, 5.6 percent on an operational 1 basis and 5.9 percent on an organic 2 basis, all compared to the prior year period. The company reported GAAP net income available to common stockholders of $327 million or $0.23 per share (EPS), compared to GAAP net income of $11 million or $0.01 per share a year ago, and achieved adjusted EPS of $0.37 for the period, compared to $0.28 a year ago.

Avantor® Reports First Quarter 2021 Results

Avantor® Reports First Quarter 2021 Results - Revenue of $1.79 billion, increase of 17.5%; organic revenue growth of 13.5% - Net income of $164.0 million; Adjusted EBITDA of $363.1 million - Diluted GAAP EPS of $0.25; adjusted EPS of $0.35 - Operating cash flow of $126.9 million; free cash flow of $111.8 million - Adjusted net leverage of 3.5x, down from 4.0x as of December 31, 2020 News provided by Share this article Share this article RADNOR, Pa., April 28, 2021 /PRNewswire/ Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies & applied materials industries, today reported financial results for the first quarter ended March 31, 2021.

Danaher Reports First Quarter 2021 Results

Danaher Reports First Quarter 2021 Results News provided by Share this article Share this article WASHINGTON, April 22, 2021 /PRNewswire/ Danaher Corporation (NYSE: DHR) (the Company ) today announced results for the first quarter 2021.  All results in this release reflect only continuing operations unless otherwise noted. For the quarter ended April 2, 2021, net earnings were $1.7 billion, or $2.29 per diluted common share which represents a 182.5% year-over-year increase from the comparable 2020 period. Non-GAAP adjusted diluted net earnings per common share were $2.52 which represents a 140.0% increase over the comparable 2020 period.  Revenues increased 58.0% year-over-year to $6.9 billion, with 30.0% non-GAAP core revenue growth including Cytiva. Operating cash flow was $1.9 billion, representing a 126.5% increase year-over-year, and non-GAAP free cash flow was $1.6 billion, representing a 135.0% increase year-over-year.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.